S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:DCPHDeciphera Pharmaceuticals Stock Price, Forecast & News

$46.90
+0.08 (+0.17 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$46.52
Now: $46.90
$48.37
50-Day Range
$46.07
MA: $52.50
$64.22
52-Week Range
$31.37
Now: $46.90
$71.11
Volume402,677 shs
Average Volume548,165 shs
Market Capitalization$2.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Deciphera Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$10.71 per share

Profitability

Net Income$-192,260,000.00

Miscellaneous

Employees112
Market Cap$2.64 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$46.90
+0.08 (+0.17 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

How has Deciphera Pharmaceuticals' stock been impacted by COVID-19?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DCPH stock has increased by 5.6% and is now trading at $46.90.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Deciphera Pharmaceuticals?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Deciphera Pharmaceuticals
.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Deciphera Pharmaceuticals
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($1.20) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.34) by $0.14.
View Deciphera Pharmaceuticals' earnings history
.

What price target have analysts set for DCPH?

15 analysts have issued 1 year price targets for Deciphera Pharmaceuticals' shares. Their forecasts range from $49.00 to $91.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $70.00 in the next year. This suggests a possible upside of 49.3% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals
.

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

Headlines about DCPH stock have trended negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the near future.
View the latest news about Deciphera Pharmaceuticals
.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Alibaba Group (BABA), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Uniqure (QURE).

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
  • Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55)

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TimesSquare Capital Management LLC (0.99%), Candriam Luxembourg S.C.A. (0.45%), Hudson Bay Capital Management LP (0.37%), Emerald Advisers LLC (0.36%), Kornitzer Capital Management Inc. KS (0.35%) and Emerald Mutual Fund Advisers Trust (0.34%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals
.

Which major investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Alps Advisors Inc., Barclays PLC, TimesSquare Capital Management LLC, Strs Ohio, SG Americas Securities LLC, Kornitzer Capital Management Inc. KS, and Algert Global LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen, and Thomas Patrick Kelly.
View insider buying and selling activity for Deciphera Pharmaceuticals
.

Which major investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Healthcare of Ontario Pension Plan Trust Fund, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Hudson Bay Capital Management LP, Bank of New York Mellon Corp, Bank of Montreal Can, and California Public Employees Retirement System.
View insider buying and selling activity for Deciphera Pharmaceuticals
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $46.90.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $2.64 billion and generates $25 million in revenue each year. The company earns $-192,260,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.